Skip to main content
Clinical Trials/ACTRN12618001784202
ACTRN12618001784202
Completed
Phase 2

acetylcysteine as an Adjunctive Treatment in treatment-resistant Post-Traumatic Stress Disorder: a randomised controlled trial

Austin Health0 sites105 target enrollmentOctober 31, 2018

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Austin Health
Enrollment
105
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 31, 2018
End Date
November 11, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • To be considered for inclusion in this study, participants are required to be aged 18 or over; have the capacity to consent to the study and to follow its instructions and procedures; fulfil the DSM\-5 diagnostic criteria for current PTSD (identified with the CAPS\-5 monthly version); have completed a course of either trauma\-focussed psychotherapy or an antidepressant; and if currently treated with an antidepressant the dose must have been stable for at least 2 weeks.

Exclusion Criteria

  • Participants are ineligible to enter the trial if they have a psychotic illness; known or suspected clinically unstable systemic medical disorder; epilepsy, recent gastrointestinal ulcers; currently use N\-acetylcysteine, selenium or Vitamin E; a history of anaphylactic reaction to N\-acetylcysteine . Female patients cannot be pregnant or lactating, and all participants must agree to using adequate contraception during the trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials